News

STRATA Skin Sciences Unveils Study Backing Its Laser Therapy

STRATA Skin Sciences Unveils Study Backing Its Laser Therapy

STRATA Skin Sciences Validates Personalized Medicine Approach

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has recently made headlines with the publication of a groundbreaking study in the field of dermatological treatment. The research, featured in a reputable medical journal, emphasizes the company’s dedication to advancing personalized medicine specifically for psoriasis. By integrating the XTRAC 308nm Excimer Laser with a targeted topical drug, STRATA demonstrates a significant improvement in patient care.

Benefits of XTRAC Excimer Laser Therapy

The published study, reflecting on clinical efficacy, showcases the promising results observed in patients suffering from plaque-type psoriasis—one of the most prevalent forms of the disease. The innovative use of the XTRAC Excimer Laser shows that it can enhance the effects of conventional topical therapies, leading to better patient outcomes.

The Study Overview

This retrospective study included 100 adult patients diagnosed with plaque-type psoriasis. Patients were strategically divided into two groups. The control group received a topical treatment regimen with 0.1% tacrolimus ointment, while the experimental group received the same topical treatment supplemented with phototherapy from the XTRAC Excimer Laser. The laser was applied twice weekly, using personalized dosing based on individual Minimum Erythema Dose (MED).

Outstanding Clinical Findings

The results of the study were compelling. Patients who received the combination treatment showcased a significantly greater reduction in the Psoriasis Area and Severity Index (PASI). The control group saw their mean PASI drop from 18.62 to 5.23, while the observation group experienced a drop from 18.36 to an impressive 3.30. Such results underscore the effectiveness of combining laser therapy with a topical agent, providing critical evidence of its superior efficacy.

Patient Safety and Treatment Personalization

Safety was another cornerstone of interest in the findings. Both treatment avenues reported no instances of serious adverse effects, although mild, self-resolving irritations were observed in a few patients. This emphasizes that the XTRAC Excimer Laser, alongside its topical formulation, is a safe and well-tolerated option for patients seeking effective psoriasis treatment.

The Power of Precision Dermatology

A standout feature of this approach is its personalized nature. The individualized dosing of the excimer laser applies a targeted approach to treatment, minimizing unnecessary exposure to healthy tissue. This principle of precision dermatology is central to improving the patient experience and outcomes. The simultaneous action of the excimer laser and the tacrolimus ointment works to address the underlying causes of psoriasis through complementary mechanisms that enhance patient care.

Expanding STRATA's Impact in Dermatology

Dr. Dolev Rafaeli, STRATA’s President and CEO, eloquently expressed confidence in the findings' implications for future clinical practices. He noted the study strengthens the position of the XTRAC technology in personalized treatment approaches and highlights increasing demand among clinicians for flexible and efficacious treatments in dermatology.

Strategic Benefits and Future Directions

The results not only highlight the potential of the XTRAC laser as a monotherapy but also reinforce the importance of combination strategies in dermatological care. Such findings validate STRATA’s strategic direction and enhance provider confidence in the treatment options available. With over 400 clinical publications supporting excimer therapy, this study serves as further evidence in ongoing discussions to expand reimbursements, navigating a landscape that increasingly favors non-biologic and in-office treatment modalities.

About STRATA Skin Sciences

STRATA Skin Sciences is committed to advancing dermatological care through innovative technology. Their range includes the XTRAC excimer laser, VTRAC lamp systems, and the TheraClear X Acne Therapy System. The company prides itself on its partnership model, enabling collaborative efforts to provide effective treatments while ensuring affordability and accessibility.

Frequently Asked Questions

What is the significance of the new study published by STRATA?

The recently published study shows enhanced patient outcomes when combining XTRAC laser therapy with topical treatment for psoriasis.

How does the combination therapy work?

The XTRAC Excimer Laser targets harmful T-cells and supports the action of tacrolimus, improving the efficacy of psoriasis treatment.

Are there any safety concerns associated with XTRAC therapy?

In the study, no serious adverse effects were reported, indicating that the treatment is generally safe.

What are the benefits of personalized treatment in dermatology?

Personalized treatments allow for targeted strategies that maximize effectiveness and minimize the risk of damaging healthy tissue, which is crucial for conditions like psoriasis.

How does STRATA support healthcare professionals?

STRATA offers a partnership model that includes training, customer service, and marketing support, ensuring healthcare professionals can effectively implement their technologies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

COP31 Puts China’s Weather-to-Energy Model on View

Updated Category News Views 76

Storm maps are becoming operating manuals, and that is the hard reality behind a November 13 COP31 event in Antalya, Türkiye. The session, “From Early Warning to Energy Action: Pathways for Global Climate Diplomacy and Cooperation,” put China’s effort to tie meteorological intelligence to energy-system decisions under an international spotlight. This is not...

Continue Reading
Teachstone’s Bronze Award Puts Classroom Quality in Focus

Updated Category News Views 0

Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 14

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 18

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 84

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 27

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 19

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 36

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading

Top 5 Most Recently Viewed Articles

3D Marketing & Services, LLC Enhances Global Presence with RADIUM

Updated Category News Views 149

3D Marketing & Services, LLC Enhances Global Presence with RADIUM LIMITED In an exciting development, 3D Marketing & Services, LLC, a dynamic digital marketing and media distribution agency, proudly announces a transformative partnership with RADIUM LIMITED. This collaboration marks a significant growth milestone for 3D Marketing, emphasizing their commitment to deliver...

Continue Reading
Aerospace Riveting Equipment Market Expected to Surge

Updated Category News Views 88

Aerospace Riveting Equipment Market Expected to Surge The aerospace riveting equipment market is on an impressive growth trajectory. Estimates indicate that this sector, valued at USD 109 million in 2023, could reach as high as USD 134 million by 2028, expanding at a compound annual growth rate (CAGR) of 4.3% during this period. Numerous factors contribute to robust...

Continue Reading
Kinetic Seas CEO Edward Honour Reflects on Last Year's Growth

Updated Category News Views 309

Kinetic Seas CEO Edward Honour Reflects on Last Year's Growth Kinetic Seas (OTC: KSEZ) has charted a remarkable journey since we took operational control just over a year ago. I am Edward Honour, your CEO and Chairman of the Board. In this letter, I will share the inspiring story of our company's evolution and the challenges we overcame along the way. Our Vision and...

Continue Reading
Investigation into The Greenbrier Companies, Inc. by Investors

Updated Category News Views 351

Investigation Overview of The Greenbrier Companies Pomerantz LLP is currently conducting an investigation on behalf of the investors of The Greenbrier Companies, Inc. (NYSE: GBX). This inquiry seeks to uncover any possible securities fraud or unlawful practices involving the company's executives. Company Financial Performance The investigation follows Greenbrier's...

Continue Reading
Exploring Charles Schwab's Remarkable Growth Over Two Decades

Updated Category News Views 169

The Growth of Charles Schwab Over Twenty Years Charles Schwab (NYSE: SCHW) has shown remarkable performance over the last two decades, consistently outperforming the market. With an annualized growth rate that eclipses broader market returns by 1.21%, investors have witnessed an impressive average annual return of 10.08%. Investment Value After 20 Years Imagine if an...

Continue Reading